for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chr Hansen Holding A/S

CHRH.CO

Latest Trade

514.00DKK

Change

-4.20(-0.81%)

Volume

397,528

Today's Range

511.20

 - 

520.40

52 Week Range

497.10

 - 

758.00

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
518.20
Open
517.40
Volume
397,528
3M AVG Volume
6.08
Today's High
520.40
Today's Low
511.20
52 Week High
758.00
52 Week Low
497.10
Shares Out (MIL)
131.69
Market Cap (MIL)
67,771.01
Forward P/E
33.32
Dividend (Yield %)
2.59

Next Event

Chr Hansen Holding A/S at Danske Bank A/S Roadshow - Los Angeles

Latest Developments

More

Chr. Hansen: Jesper Brandgaard Buys 1000 Shares In Co

Chr. Hansen Q4 EBIT Ex-Items At EUR 101.9 Mln, Below Expectations

Chr. Hansen And Lonza’s JV Receives Anti-Trust Approvals And New Name

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chr Hansen Holding A/S

Chr Hansen Holding A/S is a Denmark-based bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The Company’s business is divided into three divisions, namely Food Cultures & Enzymes, Health & Nutrition and Natural Colors. The Food Cultures & Enzymes division develops and produces cultures, enzymes and probiotics for the food industry in general and the dairy industry in particular. The Health & Nutrition division develops, produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula and animal feed industries. The Natural Colors division develops and supplies natural color solutions to the food and beverage industry, in particular the beverage, confectionery, ice cream, dairy, fruit preparation and prepared food segments. The Company operates in Europe, North and South America, as well as Asia Pacific, Middle East and Africa.

Industry

Chemical Manufacturing

Contact Info

Boege Alle 10-12

+45.45.747474

https://www.chr-hansen.com/

Executive Leadership

Dominique Reiniche

Chairman of the Board

Mauricio Graber

President, Chief Executive Officer, Member of the Executive Board

Soeren Westh Lonning

Chief Financial Officer, Executive Vice President, Member of the Executive Board

Torsten Steenholt

Executive Vice President, Global Operations

Thomas Schaefer

Executive Vice President, Chief Scientific Officer, Research & Development, Member of the Executive Board

Key Stats

3.31 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

1.1K

2018

1.1K

2019

1.2K

2020(E)

1.2K
EPS (EUR)

2017

1.680

2018

1.730

2019

1.900

2020(E)

2.065
Price To Earnings (TTM)
36.26
Price To Sales (TTM)
7.81
Price To Book (MRQ)
11.36
Price To Cash Flow (TTM)
28.84
Total Debt To Equity (MRQ)
103.09
LT Debt To Equity (MRQ)
90.76
Return on Investment (TTM)
15.56
Return on Equity (TTM)
12.76

Latest News

Latest News

BRIEF-Chr. Hansen And Lonza’s JV Receives Anti-Trust Approvals And New Name

* REG-CHR. HANSEN AND LONZA’S NEWLY BRANDED JOINT VENTURE, BACTHERA, RECEIVES ANTI-TRUST APPROVALS TO START CONTRACT MANUFACTURING OF LIVE BIOTHERAPEUTIC PRODUCTS

BRIEF-Chr Hansen And Lonza Establish Joint Venture

* ANNOUNCED ON TUESDAY WILL ESTABLISH 50/50 JOINT VENTURE WITH LONZA AG

CORRECTED-(OFFICIAL)-BRIEF-Chr. Hansen CEO buys 2,500 shares

* CEO Mauricio Graber on Jan. 17 purchased a total of 2,500 Chr. Hansen's shares at DKK 588.20 per share

BRIEF-Chr Hansen Holding Partners With Prota Therapeutics

* HOLDING A/S - NEW PARTNERSHIP TO DEVELOP TREATMENT FOR PEANUT ALLERGIES

BRIEF-Chr. Hansen Enters Partnership To Develop Treatment For Peanut Allergies

* SAYS ENTERS PARTNERSHIP WITH OF ORAL IMMUNOTHERAPY DEVELOPER PROTA THERAPEUTICS TO DEVELOP TREATMENT FOR PEANUT ALLERGIES Further company coverage: (Copenhagen newsroom)

BRIEF-Chr Hansen Updates Long Term Strategy

* SAID ON TUESDAY LONG-TERM FINANCIAL TARGET IS ORGANIC REVENUE GROWTH OF 8-10 PCT EACH YEAR FROM 2016/17 THROUGH 2021/22

BRIEF-Chr Hansen Holding Q2 EBIT Ex-Items Below Expectations At EUR 71.2 Million

* REG-07/2018 - INTERIM REPORT 1 SEPTEMBER 2017 - 28 FEBRUARY 2018

BRIEF-Chr. Hansen Holding: WCM Increases Holding In Company

* WCM INCREASED AGGREGATE HOLDING OF SHARES IN CHR. HANSEN HOLDING TO 6,598,493.50 (EQUIVALENT TO 5.00%) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

UPDATE 1-Food ingredients maker Chr Hansen falls as colour sales blench

Chr Hansen reported a weaker-than-expected first-quarter profit on Friday due to weak sales especially in its natural colours unit, sending shares in the Danish food ingredients maker down more than 7 percent.

Chr Hansen Q1 earnings disappoint, shares fall

Chr Hansen on Friday reported a weaker-than-expected first-quarter profit on weak sales especially in its natural colours unit, sending shares in the food ingredients maker down 6 percent.

BRIEF-Chr Hansen Q1 EBIT Ex-Items At EUR 64.7 Million

* Q1 REVENUE EUR 254.5 MILLION (REUTERS POLL: EUR 259 MILLION)

UPDATE 1-Shares in Denmark's Chr Hansen fall as CEO announces departure

Shares in Danish ingredients maker Chr. Hansen fell on Tuesday after its Dutch chief executive announced he would be leaving the company after five years in the post.

Chr Hansen CEO to step down, search for successor started

The chief executive of Danish ingredients maker Chr. Hansen, Cees de Jong, has decided to step down to pursue a career as a non-executive director outside the company, it announced on Tuesday.

BRIEF-Chr Hansen Holding CEO Cees De Jong too step down

* CHR HANSEN - CEES DE JONG WILL STEP DOWN AS CEO OF CHR. HANSEN HOLDING A/S Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Chr Hansen launches new bacterial range to fight food moulds

* Chr Hansen launches new generation of bio-protective bacteria

Chr. Hansen sees strong demand for probiotics to replace antibiotics in meat

Food ingredients maker Chr. Hansen is seeing strong demand for probiotics for animals as farmers and restaurant chains come under growing pressure to use fewer antibiotics in the food chain, its chief executive said.

BRIEF-Chr. Hansen ‍Q3 EBIT ex-items EUR 81.6 mln, above expectations​

* OUTLOOK FOR 2016/17 HAS BEEN NARROWED TO UPPER END OF RANGE COMPARED TO ANNOUNCEMENT OF 6 APRIL 2017

UPDATE 1-Chr. Hansen shares drop as Q2 earnings disappoint

Danish food ingredients maker Chr. Hansen posted weaker-than-expected second quarter results on Thursday, sending its shares as much as 5 percent lower and making it the second-worst performer in the FTSEurofirst 300 index.

BRIEF-Chr Hansen Q2 EBIT ex-items EUR 70.1 million; below expectations

* Q2 REVENUE EUR 259.4 MILLION (REUTERS POLL EUR 260 MILLION)

BRIEF-Chr Hansen Q1 EBIT ex-items above expectations at EUR 65.5 million

* Q1 revenue 241.7 million euros ($255.2 million) (Reuters poll 235 million euros)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up